Download Free Safe Handling Of Cytotoxic Drugs Book in PDF and EPUB Free Download. You can read online Safe Handling Of Cytotoxic Drugs and write the review.

Many Healthcare workers must deal on a daily basis with the transportation, preparation, storage, clean up, and disposal of cytotoxic drugs, which are used in chemotherapy because of their harmful effect on cancer cells. These drugs also have harmful effects on good cells, and they therefore pose a significant health risk to those who work with them. Yet there is little safety and health information available about them, and what information is available is scattered across a vast array of literature. The Safety and Health Handbook for Cytotoxic Drugs collects this information so that healthcare workers can better understand the drugs they work with and the safety and health procedures that should be followed. In it, author Samuel J. Murff presents comprehensive technical and procedural information on 106 of the most common cytotoxic drugs. The book provides guidance on quickly dealing with spills, reducing unnecessary exposure, and complying with pertinent regulations and standards in order to better equip healthcare workers to maintain a safe work environment.
This is the second edition of the WHO handbook on the safe, sustainable and affordable management of health-care waste--commonly known as "the Blue Book". The original Blue Book was a comprehensive publication used widely in health-care centers and government agencies to assist in the adoption of national guidance. It also provided support to committed medical directors and managers to make improvements and presented practical information on waste-management techniques for medical staff and waste workers. It has been more than ten years since the first edition of the Blue Book. During the intervening period, the requirements on generators of health-care wastes have evolved and new methods have become available. Consequently, WHO recognized that it was an appropriate time to update the original text. The purpose of the second edition is to expand and update the practical information in the original Blue Book. The new Blue Book is designed to continue to be a source of impartial health-care information and guidance on safe waste-management practices. The editors' intention has been to keep the best of the original publication and supplement it with the latest relevant information. The audience for the Blue Book has expanded. Initially, the publication was intended for those directly involved in the creation and handling of health-care wastes: medical staff, health-care facility directors, ancillary health workers, infection-control officers and waste workers. This is no longer the situation. A wider range of people and organizations now have an active interest in the safe management of health-care wastes: regulators, policy-makers, development organizations, voluntary groups, environmental bodies, environmental health practitioners, advisers, researchers and students. They should also find the new Blue Book of benefit to their activities. Chapters 2 and 3 explain the various types of waste produced from health-care facilities, their typical characteristics and the hazards these wastes pose to patients, staff and the general environment. Chapters 4 and 5 introduce the guiding regulatory principles for developing local or national approaches to tackling health-care waste management and transposing these into practical plans for regions and individual health-care facilities. Specific methods and technologies are described for waste minimization, segregation and treatment of health-care wastes in Chapters 6, 7 and 8. These chapters introduce the basic features of each technology and the operational and environmental characteristics required to be achieved, followed by information on the potential advantages and disadvantages of each system. To reflect concerns about the difficulties of handling health-care wastewaters, Chapter 9 is an expanded chapter with new guidance on the various sources of wastewater and wastewater treatment options for places not connected to central sewerage systems. Further chapters address issues on economics (Chapter 10), occupational safety (Chapter 11), hygiene and infection control (Chapter 12), and staff training and public awareness (Chapter 13). A wider range of information has been incorporated into this edition of the Blue Book, with the addition of two new chapters on health-care waste management in emergencies (Chapter 14) and an overview of the emerging issues of pandemics, drug-resistant pathogens, climate change and technology advances in medical techniques that will have to be accommodated by health-care waste systems in the future (Chapter 15).
Holland-Frei Cancer Medicine, Ninth Edition, offers a balanced view of the most current knowledge of cancer science and clinical oncology practice. This all-new edition is the consummate reference source for medical oncologists, radiation oncologists, internists, surgical oncologists, and others who treat cancer patients. A translational perspective throughout, integrating cancer biology with cancer management providing an in depth understanding of the disease An emphasis on multidisciplinary, research-driven patient care to improve outcomes and optimal use of all appropriate therapies Cutting-edge coverage of personalized cancer care, including molecular diagnostics and therapeutics Concise, readable, clinically relevant text with algorithms, guidelines and insight into the use of both conventional and novel drugs Includes free access to the Wiley Digital Edition providing search across the book, the full reference list with web links, illustrations and photographs, and post-publication updates
Antibody-drug conjugates (ADCs) represent a promising therapeutic approach for cancer patients by combining the antigen-targeting specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of chemotherapeutic drugs. In Antibody-Drug Conjugates, expert researchers provide detailed protocols for many of the key ADC techniques necessary for working in the field. These chapters and methodologies are aimed at the key tasks necessary to identify a suitable target, properly design the mAb, the linker and the payload, as well as to conjugate them in a reproducible and scalable fashion. Written in the highly successful Methods in Molecular BiologyTM format, these detailed chapters include the kind of practical implementation advice that guarantees quality results. Authoritative and timely, Antibody-Drug Conjugates aims to further drive ADC development and thus help toward improving cancer treatments of the future.
"Provides explanation of elements of USP Hazardous Drugs' Handling in Healthcare Settings and best practices to comply with the requirements and recommendations of the USP General Chapter"--Pref.
This book is intended as an introduction to the drug treatment of cancer. It is almost ten years since the last edition was written. In the intervening time, there have been numerous developments in cancer chemotherapy and in order to cover these the majority of the text has been completely revised and rewritten. In addition, two new chapters have been introduced, one on the safe handling of cytotoxic drugs and the other on biological response modifiers. In order to incorporate this new information without any undue increase in the length of the text the chapters on a combined approach to treatment have been omitted. This is not because interdisciplinary collaboration is no longer considered important but is a reflection of the fact that, in most centres, it has become the norm in cancer management and its central role in successful treatment no longer needs to be stressed quite so strongly. The four chapters in the last edition which dealt with the team approach to cancer therapy have been replaced by a single chapter on the place of chemotherapy in the overall treatment of cancer. Unfortunately, despite all the innovations of the last decade, it has become increasingly clear that much of the promise offered by drug treatment during the 1960s and 1970s has not been fulfilled.
The book covers the basic concept of surgical and oncosurgical disciplines as a whole, as well as the management of surgical patients from pre-op preparation to discharge, i.e., all the basics needed for a successful outcome for oncosurgical patients. It covers surgical safety, the consumer protection act, medico-legal aspects, the importance of documentation, research and publications, and managing complications. The respective chapters cover pre-operative, intra-operative, and ICU management of cancer patients, based on a multi-disciplinary approach. Additionally, they highlight recent advances in surgical oncology and so-called incurable cancers. Edited and written by an interdisciplinary team of experts in oncology and palliative care, the book is intended as a clinically useful guide to the overlapping topics of pain management in cancer patients and the treatment of cancer in patients with multiple co-morbidities like cardiovascular, respiratory disease, hypertension and diabetes mellitus. Given its scope, it will benefit multi-disciplinary oncologists, pain, palliative and intensive care experts, as well as students of surgical disciplines, from MBBS, MS and DNB, to MRCS, MCh and FRCS.
This work considers the basic concepts, definitions, and standards necessary in the design, construction, commissioning, maintenance, and use of pharmaceutical isolators.
Provides guidance for occupational hygienists, occupational health professionals and managers who are considering setting up and/or managing a biological monitoring programme for chemical exposure in the workplace. It may also be helpful to employee health and safety representatives. It gives practical advice on setting up a programme, how to protect employees' rights and what the law says about the role and use of biological monitoring guidance values. Contains an Appendix about the technical aspects of biological monitoring. Content: What is biological monitoring? What is biological effect monitoring? Health and safety law; How to set up a biological monitoring programme.